About Carmen Chang
Carmen Chang is a director at Coursera.
Form D filings name Carmen Chang as a director at Transfix.
Carmen Chang reports to the SEC as a director or major shareholder of 16 public companies, including Korro Bio (KRRO), Trevi Therapeutics (TRVI) and SpyGlass Pharma (SGP).
Carmen Chang first appears on SEC filings in 2018.
Experience
This experience comes from SEC filings. The years are when the filings name Carmen Chang in the role, so the role may have started earlier or lasted longer.
CI
Coursera, Inc.
Director
2021 – 2026 · Public company (COUR)
KI
Korro Bio, Inc.
10% owner
2023 – 2026 · Public company (KRRO)
TI
Trevi Therapeutics, Inc.
10% owner
2019 – 2026 · Public company (TRVI)
SI
NI
NeueHealth, Inc.
Director and 10% owner
2021 – 2025 · Public company (NEUE)
MI
Marker Therapeutics, Inc.
10% owner
2018 – 2024 · Public company (MRKR)
MI
MBX Biosciences, Inc.
10% owner
2024 · Public company (MBX)
SI
Savara Inc
10% owner
2021 – 2023 · Public company (SVRA)
MI
Mirum Pharmaceuticals, Inc.
10% owner
2019 – 2023 · Public company (MIRM)
AI
Akouos, Inc.
10% owner
2020 – 2022 · Public company (AKUS)
GI
Genocea Biosciences, Inc.
10% owner
2018 – 2022 · Public company (GNCA)
MI
Metacrine, Inc.
10% owner
2020 – 2021 · Public company (MTCR)
MI
Monte Rosa Therapeutics, Inc.
10% owner
2021 · Public company (GLUE)
RI
Regulus Therapeutics Inc.
10% owner
2018 – 2021 · Public company (RGLS)
BI
Black Diamond Therapeutics, Inc.
10% owner
2020 · Public company (BDTX)
XI
X4 Pharmaceuticals, Inc
10% owner
2018 · Public company (XFOR)
Key Colleagues at Startups
The people Carmen Chang works with at each company, as listed on that company's latest Form D.
Transfix, Inc. · Form D, Jun 23, 2023
JI
Jeffrey Immelt
Director
RM
Rachel Meranus
Executive officer
PH
Paul Hsiao
Director
CB
Colin Bryant
Director
TT
Tony Tzeng
Executive officer
NS
Nicholas Smolansky
Executive officer
LA
Larry Aschebrook
Director
BE
Brian Erickson
Executive officer
MB
Mike Brittain
Executive officer
JS
Jonathan Salama
Chief Executive Officer and director
AM
Andrew McElroy
Executive officer and director